This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boucher, H. W.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boucher, H. W.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2000, p. 2225-2229, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria

Helen W. Boucher,1,2 Christine B. Wennersten,1 and George M. Eliopoulos1,2,*

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215,1 and Harvard Medical School, Boston, Massachusetts 021152

Received 1 February 2000/Returned for modification 18 April 2000/Accepted 2 May 2000

The in vitro activities of GAR-936, the 9-t-butylglycylamido derivative of minocycline, were compared with those of doxycycline, minocycline, and tetracycline against 527 gram-positive clinical isolates. GAR-936 inhibited all strains, including those resistant to other tetracyclines, at concentrations of <= 2 µg/ml, except two strains of JK diphtheroids for which the MIC was 4 µg/ml.

* Corresponding author. Mailing address: Beth Israel Deaconess Medical Center, One Deaconess Rd., Boston, MA 02215. Phone: (617) 632-8586. Fax: (617) 632-7442. E-mail: geliopou{at}caregroup.harvard.edu.

Antimicrobial Agents and Chemotherapy, August 2000, p. 2225-2229, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fernandez-Roblas, R., Martin-de-Hijas, N. Z., Fernandez-Martinez, A. I., Garcia-Almeida, D., Gadea, I., Esteban, J. (2008). In Vitro Activities of Tigecycline and 10 Other Antimicrobials against Nonpigmented Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother. 52: 4184-4186 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2007). Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control. J. Clin. Microbiol. 45: 2173-2179 [Abstract] [Full Text]  
  • Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Owen, J. S. (2007). Population Pharmacokinetics of Tigecycline in Healthy Volunteers. J Clin Pharmacol 47: 727-737 [Abstract] [Full Text]  
  • Nord, C. E., Sillerstrom, E., Wahlund, E. (2006). Effect of tigecycline on normal oropharyngeal and intestinal microflora.. Antimicrob. Agents Chemother. 50: 3375-3380 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Olson, M. W., Ruzin, A., Feyfant, E., Rush, T. S. III, O'Connell, J., Bradford, P. A. (2006). Functional, biophysical, and structural bases for antibacterial activity of tigecycline.. Antimicrob. Agents Chemother. 50: 2156-2166 [Abstract] [Full Text]  
  • Jones, C. H., Tuckman, M., Howe, A. Y. M., Orlowski, M., Mullen, S., Chan, K., Bradford, P. A. (2006). Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 505-510 [Abstract] [Full Text]  
  • Bradford, P. A., Petersen, P. J., Young, M., Jones, C. H., Tischler, M., O'Connell, J. (2005). Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method. Antimicrob. Agents Chemother. 49: 3903-3909 [Abstract] [Full Text]  
  • Petersen, P. J., Bradford, P. A. (2005). Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical Isolates. Antimicrob. Agents Chemother. 49: 3910-3918 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Yin, L.-Y., Lazzarini, L., Li, F., Stevens, C. M., Calhoun, J. H. (2005). Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55: 995-1002 [Abstract] [Full Text]  
  • Ruzin, A., Visalli, M. A., Keeney, D., Bradford, P. A. (2005). Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 49: 1017-1022 [Abstract] [Full Text]  
  • Ruzin, A., Keeney, D., Bradford, P. A. (2005). AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganii. Antimicrob. Agents Chemother. 49: 791-793 [Abstract] [Full Text]  
  • Credito, K., Lin, G., Ednie, L. M., Appelbaum, P. C. (2004). Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents. Antimicrob. Agents Chemother. 48: 4033-4036 [Abstract] [Full Text]  
  • Bauer, G., Berens, C., Projan, S. J., Hillen, W. (2004). Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 53: 592-599 [Abstract] [Full Text]  
  • Kitzis, M. D., Ly, A., Goldstein, F. W. (2004). In Vitro Activities of Tigecycline (GAR-936) against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 366-367 [Full Text]  
  • Cercenado, E., Cercenado, S., Bouza, E. (2003). In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates. Antimicrob. Agents Chemother. 47: 2644-2645 [Abstract] [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Lee, C.-M., Huang, W.-K., Wu, T.-L., Wan, J.-H., Yang, D., Shyr, J.-M., Chuang, Y.-C., Yan, J.-J., Lu, J.-J., Wu, J.-J., Ko, W.-C., Chang, F.-Y., Yang, Y.-C., Lau, Y.-J., Liu, Y.-C., Leu, H.-S., Liu, C.-Y., Luh, K.-T. (2003). Telithromycin and Quinupristin-Dalfopristin Resistance in Clinical Isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47: 2152-2157 [Abstract] [Full Text]  
  • Cercenado, E., Cercenado, S., Gomez, J. A., Bouza, E. (2003). In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52: 138-139 [Full Text]  
  • Nannini, E. C., Pai, S. R., Singh, K. V., Murray, B. E. (2003). Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model. Antimicrob. Agents Chemother. 47: 529-532 [Abstract] [Full Text]  
  • Visalli, M. A., Murphy, E., Projan, S. J., Bradford, P. A. (2003). AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 47: 665-669 [Abstract] [Full Text]  
  • Lefort, A., Lafaurie, M., Massias, L., Petegnief, Y., Saleh-Mghir, A., Muller-Serieys, C., Le Guludec, D., Fantin, B. (2003). Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. Antimicrob. Agents Chemother. 47: 216-222 [Abstract] [Full Text]  
  • Milatovic, D., Schmitz, F.-J., Verhoef, J., Fluit, A. C. (2003). Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates. Antimicrob. Agents Chemother. 47: 400-404 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Crist, C. J., Mann, L., Wilson, R. W. (2002). Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous Mycobacteria. Antimicrob. Agents Chemother. 46: 3164-3167 [Abstract] [Full Text]  
  • Betriu, C., Rodriguez-Avial, I., Sanchez, B. A., Gomez, M., Alvarez, J., Picazo, J. J. (2002). In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain. Antimicrob. Agents Chemother. 46: 892-895 [Abstract] [Full Text]  
  • Chopra, I., Roberts, M. (2001). Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiol. Mol. Biol. Rev. 65: 232-260 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»